Publications by authors named "Caroline Shadowen"
Anti-NMDA receptor (A-NMDAR) encephalitis is an autoimmune condition often associated with ovarian teratoma. Surgical removal of the teratoma is generally curative, and recurrence is uncommon. A 14-year-old female presented with psychiatric symptoms and was ultimately diagnosed with A-NMDAR encephalitis during a prolonged hospitalization.
View Article and Find Full Text PDFArticle Synopsis
- Herpes simplex (HSV) and varicella zoster (VZV) are serious concerns during pregnancy due to their potential to harm both mother and baby through direct infection and complications.
- A case involving a 19-year-old pregnant woman with VZV symptoms was successfully treated with acyclovir, leading to a healthy delivery.
- It is crucial to investigate genital lesions for VZV in pregnant patients, especially those lacking immunity, to develop effective management and ensure safety for mother and baby during childbirth.
Introduction: Opioid use disorder (OUD) is a leading cause of pregnancy-associated deaths. OUD treatment with buprenorphine (BUP) reduces overdose risk and improves perinatal outcomes. Incarceration can be a barrier to receipt of OUD treatment during pregnancy and postpartum.
View Article and Find Full Text PDFWhat Recovery Means to Postpartum Women in Treatment for Opioid Use Disorder.
Womens Health Rep (New Rochelle)
January 2022
Article Synopsis
- Opioid overdoses are a significant cause of pregnancy-related deaths, especially within the first year after giving birth, prompting a study on recovery for postpartum women in treatment for opioid use disorder.
- This mixed-methods research involved women 2-6 months postpartum from a perinatal addiction clinic, utilizing surveys and interviews to explore their definitions of recovery and related experiences.
- Participants viewed recovery as a transformative process focused on personal growth, resilience, and various life improvements, with medication for opioid use disorder playing a crucial role in their recovery journey.
Objectives: For women with opioid use disorder (OUD), the postpartum period is an especially vulnerable period. Buprenorphine (BUP) improves OUD outcomes during this timeframe. Once-monthly injectable BUP (XRI-BUP) is a newer formulation for which evidence of use in postpartum women is extremely limited.
View Article and Find Full Text PDFBackground: Knowledge of medical conditions and their evidence-based medications varies among individuals. This range of knowledge may affect attitudes and influence medical decision-making of both patients and providers. Perceptions may be even more impactful in pregnancy, a timeframe subject to bias, and in diseases that include behavioral symptoms and often carry significant societal stigma, such as opioid use disorder (OUD).
View Article and Find Full Text PDFBuprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.
Curr Treat Options Psychiatry
September 2020
Purpose Of Review: Opioid-related deaths are a leading cause of mortality during pregnancy through 12 months postpartum. Buprenorphine use during pregnancy is increasing, yet expert opinion on its dosing through the perinatal period is limited. We provide a review of the current clinical literature on buprenorphine dosing during pregnancy through 12 months postpartum.
View Article and Find Full Text PDF